Abstract
Association studies between Alpha-1-antichymotrypsin (ACT)-17(A>T) polymorphisms and Alzheimer’s disease (AD) susceptibility have shown conflicting results. In this investigation, we performed a meta-analysis to assess the purported associations. Subgroup analyses based on ethnicity (Caucasians, East-Asian and American mixed) were also performed including a total of 5,676 AD patients and 5,460 controls for ACT-17. Overall, allele contrast (A vs. T) of ACT -17 polymorphism produced significant results in the worldwide population [Pheterogeneity=0.01, random-effects (RE) odds ratio (OR) 1.12; 95% CI 1.04-1.21, P=0.003] and in the Caucasian population [Pheterogeneity=0.03, RE OR1.11 95% CI 1.01-1.24, P=0.04]. Meta-analyses of other genetic contrasts suggested that the A allele carriers are associated with increased susceptibility to AD in variant populations. No significant association was observed in the East-Asian subgroup analysis. In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
Keywords: Abeta-peptide, Alpha-1-antichymotrypsin, Alzheimer’s disease, meta-analysis polymorphism, susceptibility
Current Alzheimer Research
Title:The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis
Volume: 10 Issue: 1
Author(s): Chao Dou, Jiyuan Zhang, Yang Sun, Xin Zhao, Qihan Wu, Chaoneng Ji, Shaohua Gu, Yi Xie and Yumin Mao
Affiliation:
Keywords: Abeta-peptide, Alpha-1-antichymotrypsin, Alzheimer’s disease, meta-analysis polymorphism, susceptibility
Abstract: Association studies between Alpha-1-antichymotrypsin (ACT)-17(A>T) polymorphisms and Alzheimer’s disease (AD) susceptibility have shown conflicting results. In this investigation, we performed a meta-analysis to assess the purported associations. Subgroup analyses based on ethnicity (Caucasians, East-Asian and American mixed) were also performed including a total of 5,676 AD patients and 5,460 controls for ACT-17. Overall, allele contrast (A vs. T) of ACT -17 polymorphism produced significant results in the worldwide population [Pheterogeneity=0.01, random-effects (RE) odds ratio (OR) 1.12; 95% CI 1.04-1.21, P=0.003] and in the Caucasian population [Pheterogeneity=0.03, RE OR1.11 95% CI 1.01-1.24, P=0.04]. Meta-analyses of other genetic contrasts suggested that the A allele carriers are associated with increased susceptibility to AD in variant populations. No significant association was observed in the East-Asian subgroup analysis. In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
Export Options
About this article
Cite this article as:
Dou Chao, Zhang Jiyuan, Sun Yang, Zhao Xin, Wu Qihan, Ji Chaoneng, Gu Shaohua, Xie Yi and Mao Yumin, The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis, Current Alzheimer Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567205011310010009
DOI https://dx.doi.org/10.2174/1567205011310010009 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Alpha7 Neuronal Nicotinic Receptor: A Pluripotent Target for Diseases of the Central Nervous System
CNS & Neurological Disorders - Drug Targets Use of Mental Health Services By Youths Who Have Sexually Offended
Adolescent Psychiatry Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Current Pharmaceutical Biotechnology Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]
Medicinal Chemistry Reviews - Online (Discontinued) New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research Vitamin D Levels in Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome
Current Vascular Pharmacology Computational Drug Repositioning for Cancer Therapeutics
Current Topics in Medicinal Chemistry Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer’s Disease
Current Alzheimer Research Anti-inflammatory Effects of Rosuvastatin in Healthy Subjects: A Prospective Longitudinal Study
Current Pharmaceutical Design Evaluating High-Dose Rivastigmine Patch in Severe Alzheimer’s Disease: Analyses with Concomitant Memantine Usage as a Factor
Current Alzheimer Research NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry A Prospective Study for Introducing Insulin Pens and Safety Needles in a Hospital Setting. The SANITHY Study
Current Diabetes Reviews Development and Evaluation of a Tactile Cognitive Function Test Device for Alzheimer’s Disease Early Detection
Neuroscience and Biomedical Engineering (Discontinued)